Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 990 | 1187 | 1091 | 830 | 1404 | 2000 |
Fund Return | -1.01% | 18.66% | 9.11% | -6.02% | 7.01% | 7.18% |
Place in category | 379 | 322 | 362 | 431 | 427 | 356 |
% in Category | 62 | 53 | 64 | 83 | 88 | 90 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
TIAA-CREF Equity Index Instl | 17.5B | 19.66 | 7.61 | 12.41 | ||
TIAA-CREF International Eq Idx Inst | 14.95B | 7.00 | 2.80 | 5.33 | ||
TIAA-CREF Large-Cap Gr Idx Instl | 14.23B | 24.07 | 8.79 | 16.12 | ||
TIAA-CREF Large-Cap Value Idx Inst | 9.81B | 15.32 | 6.81 | 8.83 | ||
TIAA-CREF S&P 500 Index Instl | 7.91B | 20.90 | 9.03 | 12.94 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Principal MidCap Institutional | 15.13B | 18.77 | 5.53 | 12.65 | ||
T. Rowe Price Mid-Cap Growth I | 13.72B | 7.79 | 0.27 | - | ||
T. Rowe Price Mid-Cap Growth | 12.77B | 7.68 | 0.14 | 10.48 | ||
Vanguard Mid-Cap Growth Index Admir | 12.09B | 11.75 | -0.99 | 10.25 | ||
T. Rowe Price New Horizons I | 11.02B | 3.91 | -9.99 | - |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Cimpress NV | IE00BKYC3F77 | 4.92 | 81.09 | -2.87% | |
DexCom | US2521311074 | 3.29 | 77.94 | +0.14% | |
Verisk | US92345Y1064 | 2.91 | 294.75 | +1.12% | |
Transdigm | US8936411003 | 2.37 | 1,262.61 | +0.13% | |
HubSpot Inc | US4435731009 | 2.23 | 729.83 | -0.27% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review